Hypofractionated Boost vs Conventionally Fractionated Boost for Localized High Risk Prostate Cancer

Official Title

Randomized Trial of Concomitant Hypofractionated IMRT Boost Versus Conventional Fractionated IMRT Boost for Localized High Risk Prostate Cancer


Randomized trial comparing 2 external beam radiation therapy fractionation schemes in patients with localized high risk prostate cancer. Primary endpoint is acute toxicity.

Trial Description

Primary Outcome:

  • Acute Toxicity
Secondary Outcome:
  • Late Toxicity
  • Biochemical Control (Phoenix Definition)
  • Overall Survival
Patients enrolled onto this study will be randomized to one of the following treatment arms:
  • Standard fractionation: Using 2 sequential IMRT plans, the pelvic lymph nodes and prostate will initially be treated to 46 Gy in 23 fractions, followed by a subsequent boost to the prostate to a total dose of 78 Gy.
  • Hypofractionation: Using a one phase IMRT plan, the pelvic lymph nodes will be treated to a dose of 48 Gy in 25 fractions, while the prostate will be treated to a dose of 68 Gy in 25 fractions concomitantly (simulataneous integrated boost). In addition, all patients receive 1.5- 3 years of androgen deprivation therapy.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society